WINNIPEG, MANITOBA (AMEX: MCU), a cardiovascular drug discovery
and development company, today announced that David Banks has
joined its Board of Directors. Mr. Banks brings to the Board more
than 35 years of international investment banking and private
equity investing experience.
"Mr. Banks possesses extensive investment banking knowledge that
will be invaluable as we build greater shareholder value," stated
Medicure's President and CEO, Albert D. Friesen, PhD. "Mr. Banks
has forged an outstanding reputation as a business leader and
advisor, and Medicure will benefit greatly from his strategic
insight and capital market experience."
"I am pleased to be working with the Company at such an exciting
time in its history," stated David Banks. "Medicure has an
innovative cardiovascular product portfolio, with significant
market opportunities. I look forward to utilizing my experiences
and knowledge to further the Company's success."
About David Banks
Mr. Banks is presently a Principal of Carlyle Banks &
Company Inc., a Toronto-based investment banking firm. Mr. Banks
also brings to the Board nearly 20 years of experience at The Chase
Manhattan Bank where he held various roles including Senior Vice
President. The Chase Manhattan Bank, now known as JPMorgan Chase,
is a leading global financial services firm with assets of $1.5
trillion.
Additionally, Mr. Banks has served as AT&T Capital
Corporation's Chief Executive Officer. AT&T Capital was the
fifth largest leasing company in the world, operating in 26
countries.
Prior to his current role at Carlyle Banks & Company, Mr.
Banks held the position of Vice Chairman of Lawrence & Company
Inc., a Toronto-based global asset management firm with interests
and investments in various sectors in Canada and throughout the
world.
Mr. Banks' appointment to Medicure's Board of Directors is
subject to regulatory approval.
Medicure's Board now consists of:
- Albert D. Friesen, PhD (Chairman), President & CEO,
Medicure Inc.
- David Banks, JD, Independent Corporate Director, Principal of
Carlyle Banks & Company Inc.
- Kishore Kapoor, CA, (Chair, Audit and Finance Committee),
Independent Corporate Director, President, Wellington West Holdings
Inc., Co-Founder of Assante Corporation
- Gerald McDole, MBA, Independent Corporate Director, Past
President AstraZeneca Canada Inc.
- Arnold Naimark, MD, F.R.C.P. �, F.R.S.C, (Chair, Executive
Compensation, Nominating and Corporate Governance Committee),
Independent Corporate Director, Director of the University of
Manitoba Centre for the Advancement of Medicine, and Past President
of the University of Manitoba
- Peter Quick, BE, Independent Corporate Director, Past
President and CEO of Quick & Reilly, Inc. and former President
of the American Stock Exchange
About Medicure Inc.
Medicure is a biopharmaceutical company focused on the research,
development and commercialization of novel compounds to treat
cardiovascular disorders. The Company's solid position in this
field is highlighted by the following:
- Lead compound MC-1 in pivotal Phase 3 study for FDA
approval
- Four positive Phase 2 trials completed with MC-1
- FDA Fast Track designation for MC-1
- U.S. rights to AGGRASTAT� Injection (tirofiban
hydrochloride)
- Combination of MC-1 and lisinopril (MC-4232) completed Phase
2
- Dual action antithrombotic, MC-45308, with positive
preclinical results
Medicure also has a medicinal chemistry based Drug Discovery
program focused on discovery and advancement of novel small
molecule anti-ischemics and antithrombotics towards human clinical
studies.
This press release contains forward-looking statements, as
defined under applicable securities legislation, that involve
risks, which may cause actual results to differ materially from the
statements made, and accordingly may be deemed to be
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements are made as of the date hereof, and
the Company disclaims any intention and has no obligation or
responsibility to update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise
except as required by law. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements. Such factors
include, among others, the Company's stage of development, lack of
product revenues, additional capital requirements, risks associated
with the completion of clinical trials and obtaining regulatory
approval to market the Company's products, the ability to protect
its intellectual property, dependence on collaborative partners and
the ability to meet its debt obligations. These factors should be
considered carefully and readers are cautioned not to place undue
reliance on such forward-looking statements. Additional risks and
uncertainties relating to the Company and its business can be found
in the "Risk Factors" section of its Form 20F for the year ended
May 31, 2007.
Contacts: Medicure Inc. Derek Reimer Chief Financial Officer
1-888-435-2220 Medicure Inc. Adam Peeler Manager of Investor &
Public Relations 1-888-435-2220 (204) 488-9823 (FAX) Email:
info@medicure.com Website: www.medicure.com
Medicure (AMEX:MCU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medicure (AMEX:MCU)
Historical Stock Chart
From Jul 2023 to Jul 2024